January 17, 2012 – Terumo Americas Holding Inc., a U.S. subsidiary of Japan's Terumo Corp., announced it acquired Onset Medical Corp., which develops interventional procedural access sheath technology for cardiology and urology.

January 17, 2012 — The U.S. Food and Drug Administration (FDA) expanded the approved usage for an endovascular graft manufactured by W.L. Gore and Associates Inc. to include treatment of life-threatening tears or ruptures of the aorta (thoracic aortic transection).

 

January 17, 2012 – Nonstop nosebleeds can be serious and frightening, often sending people to the emergency room, where their noses are packed with gauze. When that doesn’t work, nosebleeds can be halted by injecting microscopic particles – made of the same material as a kitchen sponge – into the arteries that supply the nose.

January 17, 2012 — Killing tumors by freezing them can add precious time to the lives of women with ovarian cancer that has spread to other parts of the body. Minimally invasive cryoablation extends lives and is cost-effective, according to a study being presented at the 4th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).

January 16, 2012 — Endosense has announced the European launch of the TactiCath 75 force-sensing ablation catheter as well as results of the EFFICAS clinical study of contact force-sensing in catheter ablation procedures.

January 16, 2012 — Philips Healthcare announced the enrollment of the first patients in its CHILL-MI clinical study. The RAPID MI-ICE trial showed a 38 percent reduction in infarct size in STEMI patients who were cooled to a temperature of less than 35° C prior to performing angioplasty.

January 12, 2012 — Clinical analytics company Humedica announced the launch of a predictive analytic model that identifies patients at high-risk for a congestive heart failure (CHF) hospitalization. 

January 13, 2012 – The U.S. Food and Drug Administration (FDA) is updating healthcare professionals and the public about preliminary findings from ongoing investigations following the voluntary recall of CardioGen-82 last July by the manufacturer, Bracco Diagnostics. CardioGen-82 consists of a generator that is used at clinical sites to produce rubidium (Rb)-82 chloride injection. A CardioGen-82 positron emission tomography (PET) scan is one of a variety of nuclear medicine scans that use radioactive drugs to evaluate myocardial perfusion.

 

January 13, 2012 — Amorcyte Inc., a NeoStem Inc. company, announced the expansion of intellectual property protection around its lead product candidate, AMR-001, with the grant of U.S. patent number 8,088,370 by the United States Patent and Trademark Office. Amorcyte's first issued patent (7,794,705) entitled "Compositions and Methods of Vascular Injury Repair," protects a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction (AMI). The new patent covers the use of AMR-001 in the repair of any vascular injury caused by vascular insufficiency, and effectively expands the breadth of the patented claims beyond the current target indications for AMR-001.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now